IRCT201008312641N3
Completed
Phase 4
Multicenter, Open-Label, Phase IV Study to Evaluate the Safety,Tolerability, and Efficacy of Tocilizumab in Patients with Active Rheumatoid arthritis on background non-biologic DMARDs who have an inadequate response to current non-biologic DMARD and/or Anti- TNF therapy
Akbarieh Company0 sites100 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Rheumatoid Arthritis.
- Sponsor
- Akbarieh Company
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion Criteria: age more than 18 years, moderate to severe rheumatoid arthritis (DAS28 \>3\.2\) of 6 months duration, inadequate clinical response to non\-biologic DMARDs or anti\-TNF, body weight less than150 kg
Exclusion Criteria
- •rheumatic autoimmune disease or inflammatory joint disease other than RA, major surgery within 8 weeks prior to screening or planned major surgery within 6 months following screening
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
A Study to Evaluate Overall Health, Physical Activity and Joint Outcomes, in Participants with Severe or Moderate Hemophilia A without FVIII Inhibitors on Emicizumab ProphylaxisSevere or Moderate Hemophilia AMedDRA version: 20.0Level: LLTClassification code: 10053753Term: Hemophilia A without inhibitors Class: 10010331Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]CTIS2023-505747-40-00F. Hoffmann-La Roche AG136
Active, not recruiting
Phase 4
An Open Label, Multicentre, Phase IV Study to Evaluate the Safety and Treatment Effects of Tebokan® forte (Ginkgo Biloba EGb 761®) One Tablet of 120 mg Twice Daily in Adult Patients with DementiaHealth Condition 1: null- Patients diagnosed with dementia including Alzheimers disease vascular dementia or mixed dementiaCTRI/2017/02/007764Dr Willmar Schwabe India Pvt Ltd150
Active, not recruiting
Not Applicable
A study to determine the safety profile of CSL Limited's Influenza Virus Vaccine in a pediatric population aged greater than or equal to 6 months to less than 18 years.Influenza, humanTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2014-004131-40-Outside-EU/EEACSL Limited2,025
Active, not recruiting
Phase 1
An Open-Label, Multicenter Phase IV Study assessing safety and efficacy of ribavirin (Copegus®) as part of combination therapy with peginterferon alfa-2a (Pegasys®) in selected groups of patients with chronic viral hepatitis CEUCTR2005-003932-23-SKRoche spol. s r.o.385
Active, not recruiting
Not Applicable
An Open-Label, Multicenter Phase IV Study assessing safety and efficacy of ribavirin (Copegus®) as part of combination therapy with peginterferon alfa-2a (Pegasys®) in selected groups of patients with chronic viral hepatitis COtevrená, multicentrická studie fáze IV hodnotící bezpecnost a úcinnost ribavirinu (Copegus®) v kombinované lécbe s peginterferonem alfa-2a (Pegasys®) u vybraných skupin pacientu s chronickou virovou hepatitidou typu C.An Open-Label, Multicenter Phase IV Study assessing safety and efficacy of ribavirin (Copegus®) as part of combination therapy with peginterferon alfa-2a (Pegasys®) in selected groups of patients with chronic viral hepatitis CEUCTR2005-003932-23-CZRoche spol. s r.o.300